Targeted Therapies Forum 2022: In this video Dr. Narjust Florez addresses the complicated question of progression for a patient with stage 4 ALK+ disease who developed new lesions after reducing Alectinib.
We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.